<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432523</url>
  </required_header>
  <id_info>
    <org_study_id>V205C-011</org_study_id>
    <secondary_id>X04-MMRr-301</secondary_id>
    <nct_id>NCT00432523</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)</brief_title>
  <official_title>An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of&#xD;
      age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as&#xD;
      immunogenic as a single dose of M-M-RTMII administered by SC route in terms of response rates&#xD;
      to measles, mumps and rubella at 42 days following the vaccination.&#xD;
&#xD;
      AND/OR&#xD;
&#xD;
      To compare if, when given concomitantly with M-M-RTMII by the same route at 12-18 months of&#xD;
      age using separate injection sites, a single dose of VARIVAX® administered by IM route is as&#xD;
      immunogenic as a single dose of VARIVAX® administered by SC route in terms of response rate&#xD;
      to varicella at 42 days following the vaccination&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To summarise the antibody titres to measles, mumps, rubella and varicella at 42 days&#xD;
           following the vaccination in children immunised with M-M-R™II and VARIVAX® administered&#xD;
           concomitantly at two separate injection sites by the same route IM or SC,&#xD;
&#xD;
        -  To evaluate the safety profiles of M-M-R™II and VARIVAX® administered concomitantly at&#xD;
           two separate injection sites by the same route IM or SC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2005</start_date>
  <completion_date type="Actual">September 5, 2005</completion_date>
  <primary_completion_date type="Actual">September 5, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>752</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Varicella</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subject of either gender,&#xD;
&#xD;
          2. Age 12 to 18 months ,&#xD;
&#xD;
          3. Consent form signed by both parent(s) or by the legal representative properly informed&#xD;
             about the study,&#xD;
&#xD;
          4. Parent(s) / legal representative able to understand the protocol requirements and to&#xD;
             fill in the Diary Card.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in&#xD;
             combination vaccine,&#xD;
&#xD;
          2. Known or suspected clinical history of infection with measles, mumps, rubella,&#xD;
             varicella or zoster,&#xD;
&#xD;
          3. Any recent (≤30 days) exposure to measles, mumps or rubella,&#xD;
&#xD;
          4. Any recent (≤30 days) exposure to varicella or zoster involving:&#xD;
&#xD;
          5. Any recent (≤3 days) history of febrile illness&#xD;
&#xD;
          6. Any severe chronic disease,&#xD;
&#xD;
          7. Active untreated tuberculosis,&#xD;
&#xD;
          8. Known personal history of seizures,&#xD;
&#xD;
          9. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant&#xD;
             neoplasms affecting the bone marrow or lymphatic systems,&#xD;
&#xD;
         10. Any severe thrombocytopenia or any other coagulation disorder that would&#xD;
             contraindicate intramuscular injection,&#xD;
&#xD;
         11. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed&#xD;
&#xD;
         12. Any recent tuberculin test (≤7 days) or scheduled tuberculin test through visit 2,&#xD;
&#xD;
         13. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived&#xD;
             products or scheduled to be administered through visit 2,&#xD;
&#xD;
         14. Any recent receipt of an inactivated or a live vaccine (≤30 days) or scheduled&#xD;
             vaccination through visit 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne FIQUET, MD</last_name>
    <role>Study Director</role>
    <affiliation>SPMSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of : Measles, Mumps, Rubella and Varicella diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

